Alembic Pharmaceuticals surges on getting EIR for Solid Oral Formulation Facility at Vadodara
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Alembic Pharmaceuticals is currently trading at Rs. 574.85, up by 3.10 points or 0.54% from its previous closing of Rs. 571.75 on the BSE.
The scrip opened at Rs. 573.85 and has touched a high and low of Rs. 582.85 and Rs. 563.65 respectively. So far 3516 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 775.00 on 24-May-2022 and a 52 week low of Rs. 463.30 on 29-Mar-2023.
Last one week high and low of the scrip stood at Rs. 599.00 and Rs. 550.40 respectively. The current market cap of the company is Rs. 11318.10 crore.
The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 17.86% and 12.53% respectively.
Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at company’s Solid Oral Formulation Facility (F-4) at Jarod, Vadodara during the period from December 08, 2022 to December 16, 2022. This was pre-approval inspection to cover Solid Oral drug products for which ANDAs were filed with USFDA. The Company had also started receiving approvals manufactured at this facility.
Alembic has a total of five drug product manufacturing facilities and two drug substance manufacturing facilities. All these facilities are inspected and accepted by USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
